C17. Novel Therapeutics and Biomarkers for Idiopathic Pulmonary Fibrosis 2022
DOI: 10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a3721
|View full text |Cite
|
Sign up to set email alerts
|

N23Ps as a Novel Highly Potent Antifibrotic Therapeutic Compound Class and Discovery of Its Mode of Action in a Human Ex Vivo Fibrosis Model

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles